BRTX-100 Front and Center at ORS 2025
– New blinded preliminary BRTX-100 data described this past Saturday at prestigious “2025 Winners in Industry Innovations in MSK Health”...
– New blinded preliminary BRTX-100 data described this past Saturday at prestigious “2025 Winners in Industry Innovations in MSK Health”...
ROSEMONT, Ill., Feb. 7, 2025 /PRNewswire/ -- Nicolas S. Piuzzi, MD, was recognized as the 2025 Kappa Delta Young Investigator Award...
MIAMI, FL, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
MIAMI, FL, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era...
TORRINGTON, Conn., Jan. 29, 2025 /PRNewswire/ -- Therap Services, the premier provider of HIPAA-compliant electronic documentation solutions for organizations and...
MINNEAPOLIS, Jan. 29, 2025 /PRNewswire/ -- Joshin, a leading provider of neurodivergent and disability support services, and Integrate Autism Employment...
HANOVER, Mass., Jan. 29, 2025 /PRNewswire/ -- The Brain Aneurysm Foundation (BAF), the leading advocacy organization supporting education, research, and policy to...
PITMAN, N.J., Jan. 28, 2025 /PRNewswire/ -- The American Academy of Ambulatory Care Nursing (AAACN) invites nurses, health care organizations, and communities...
Event will showcase results of Company's pivotal PRIME study and include the principal investigator SALT LAKE CITY, Jan. 27, 2025...
LAS VEGAS, Jan. 21, 2025 /PRNewswire/ -- The Consumer Technology Association (CTA)® Foundation wrapped up an exciting and impactful week at...
--128 enrolled participants, as of December 31, 2024, exceeds initial target of 90 participants-- --150 maximum participant enrollment projected by...
Collaboration delivers strategic Neurodiversity initiatives, with comprehensive support and advanced analytics and insights tailored to both individual and organizational needs....
Magdalena aiming to submit Investigational New Drug (IND) application in early 2025 to the FDA for a next-generation psychoactive prescription...
MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a...
RESTON, Va., Jan. 6, 2025 /PRNewswire/ -- Leidos (NYSE:LDOS) today announced that its wholly owned subsidiary, QTC Medical Services, operating under the...
MIAMI, FL, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”),...
VYVDURA® now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP argenx's VYVGART® and VYVDURA portfolio...
Leland to discuss his best-selling book, “The Country of the Blind: A Memoir at the End of Sight” LOS ANGELES,...